Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
3,476
datasets available to search
ShareScore release 0.9.0
Dataset results
3,476 results for “Parkinsons Disease”
Parkin regulates amino acid homeostasis at mitochondria-lysosome (M/L) contact sites in Parkinson's disease
<p>Mutations in the E3 ubiquitin ligase parkin are the most common cause of early-onset Parkinson's disease (PD). Although parkin modulates mitochondrial and endolysosomal homeostasis during cellular stress, whether parkin regulates mitochondrial and lysosomal crosstalk under physiologic conditions remains unresolved. Using transcriptomics, metabolomics, and super-resolution microscopy, we identify amino acid metabolism as a disrupted pathway in iPSC-derived dopaminergic neurons from parkin PD patients. Compared to isogenic controls, parkin mutant neurons exhibit decreased mitochondria-lysosome contacts via destabilization of active Rab7. Subcellular metabolomics in parkin mutant neurons reveals amino acid accumulation in lysosomes and their deficiency in mitochondria. Knockdown of the Rab7 GTPase-activating protein TBC1D15 restores mitochondria-lysosome tethering and ameliorates cellular and subcellular amino acid profiles in parkin mutant neurons. Our data thus uncover a function of parkin in promoting mitochondrial and lysosomal amino acid homeostasis through stabilization of mitochondria-lysosome contacts and suggest that modulation of inter-organelle contacts may serve as a potential target for ameliorating amino acid dyshomeostasis in disease.</p>
A five-sensor IMU-based Parkinson's disease patient and control dataset including three activities of daily living
<p class="MsoNormal">Parkinson's disease is an often-debilitating progressive neurological condition leading to loss of motor control. This dataset contains kinematic sensor data from two groups: one containing 15 patients with Parkinson's disease, and a control group of 19 participants without any known neurological condition. Participant ages ranged from 40–85, 21 were male, and 13 were female. The participants wore five 9-axis Inertial Measurement Units (IMUs) – one on each upper arm, each lower arm, and on their head. They were asked to perform a calibration pose, followed by three activities: making toast, putting on a cardigan, and unlocking and opening a door, with each activity repeated three times. The IMUs recorded time-series acceleration and orientation data from the moment where the participant was instructed to begin the activity (inception of the idea to act), through to the activity's completion. This dataset is planned for use in intent-sensing studies for assistive device control but is also applicable for activity recognition.</p>
Data from: Developmental exposure to the Parkinson's disease-associated organochlorine pesticide dieldrin alters dopamine neurotransmission in α-synuclein pre-formed fibril (PFF)-injected mice
<p>Parkinson's disease (PD) is the fastest-growing neurological diseases worldwide, with increases outpacing aging and most rapid in recently industrialized areas, suggesting the role of environmental factors. Together, epidemiological studies, post-mortem analysis and mechanistic studies suggest that exposure to persistent organic pollutants, including the organochlorine pesticide dieldrin, increases PD risk. In mouse models, developmental dieldrin exposure causes male-specific exacerbation of neuronal susceptibility to MPTP and synucleinopathy. Specifically, developmental dieldrin exposure induces male-specific exacerbation of toxicity in the α-synuclein (α-syn) pre-formed fibril (PFF) model with increased deficits in striatal dopamine (DA) turnover and motor deficits on the challenging beam. Here, we hypothesized that alterations in DA handling contribute to the observed changes and assessed vesicular monoamine transporter 2 (VMAT2) function and DA release in this dieldrin/PFF two-hit model. Female C57BL/6 mice were exposed to 0.3 mg/kg dieldrin or vehicle every 3 days by feeding, starting at 8 weeks of age by ingestion and continuing throughout breeding, gestation, and lactation. Male offspring from independent litters underwent unilateral, intrastriatal injections of α-syn PFFs at 12 weeks of age and vesicular <sup>3</sup>H-DA uptake assays and fast-scan cyclic voltammetry (FSCV) were performed at 4 months post-PFF injection. We observed a dieldrin-induced increase in DA release in striatal slices in PFF-injected animals, but no change in VMAT2 activity. These results suggest that developmental dieldrin exposure increases a compensatory response to synucleinopathy-triggered striatal DA loss and supports our hypothesis that alterations in DA handling may underly the observed exacerbation of PFF-induced deficits in motor behavior and DA turnover.</p>
Assessing the Maturity level of Wearable Sensors for Home Monitoring in Parkinson's Disease through Evidence Evaluation Levels (EEL) and User Experience: A Comprehensive Review
<p>Source files for the PRISMA diagram and Figure 1 of the comprehensive review: Assessing the Maturity level of Wearable Sensors for Home Monitoring in Parkinson’s Disease through Evidence Evaluation Levels (EEL) and User Experience</p>
Support for Physical Activity in Everyday Life With Parkinson's Disease
ClinicalTrials.gov study NCT05510739. IPD Sharing: NO. Countries: 1. Publications: 1.
PF-06669571 In Subjects With Idiopathic Parkinson's Disease
ClinicalTrials.gov study NCT02565628. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease
ClinicalTrials.gov study NCT03318523. IPD Sharing: YES. Countries: 9. Publications: 3.
A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).
ClinicalTrials.gov study NCT00974974. IPD Sharing: NO. Countries: 8. Publications: 2.
Kick Out Parkinson's Disease 2
ClinicalTrials.gov study NCT03882879. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Physical Therapy and Deep Brain Stimulation in Parkinson Disease
ClinicalTrials.gov study NCT03181282. IPD Sharing: NO. Countries: 1. Publications: 1.
Repetitive Transcranial Magnetic Stimulation for Musculoskeletal Pain in Patients With Parkinson's Disease
ClinicalTrials.gov study NCT05537597. IPD Sharing: NO. Countries: 1. Publications: 6.
Coping With Depression in Parkinson's Disease
ClinicalTrials.gov study NCT00464464. IPD Sharing: Not stated. Countries: 1. Publications: 6.
A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
ClinicalTrials.gov study NCT03305809. IPD Sharing: YES. Countries: 3. Publications: 2.
Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease
ClinicalTrials.gov study NCT02006121. IPD Sharing: NO. Countries: 7. Publications: 2.
Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms
ClinicalTrials.gov study NCT00297778. IPD Sharing: Not stated. Countries: 13. Publications: 1.
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
ClinicalTrials.gov study NCT00909545. IPD Sharing: Not stated. Countries: 2. Publications: 35.
A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis
ClinicalTrials.gov study NCT02969369. IPD Sharing: YES. Countries: 1. Publications: 1.
Evaluation of Using Vibrotactile Coordinated Reset for Management of Parkinson's Disease
ClinicalTrials.gov study NCT03857867. IPD Sharing: NO. Countries: 1. Publications: 1.
Amped-PD: Amplifying Physical Activity Through Music in Parkinson Disease
ClinicalTrials.gov study NCT05421624. IPD Sharing: NO. Countries: 1. Publications: 12.
Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease
ClinicalTrials.gov study NCT02847650. IPD Sharing: YES. Countries: 4. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.